中文摘要：

目的：评价奥司他韦治疗妊娠期流感病毒感染的安全性。方法：计算机检索PubMed、The Cochrane library、EMbase、CNKI、WanFang data、维普、CBM数据库。按纽卡斯-渥太华量表（NOS量表）评价纳入研究质量后,对同质研究采用RevMan5.3进行Meta分析。结果：本研究共纳入6篇队列研究进行分析,奥司他韦暴露组共1 865例,非暴露组共138 414例。结果显示奥司他韦暴露组胎膜早破发生率与非暴露组比较,差异有统计学意义（P〈0.05）,奥司他韦暴露组胎膜早破发生率低于非暴露组;而在早产、先兆子痫及产时发热方面,2组比较差异均无统计学意义（P〉0.05）;在死胎或新生儿死亡发生率和阿普加评分〈7分方面,奥司他韦暴露组与非暴露组比较,差异均无统计学意义（P〉0.05）;而在胎儿畸形和小样儿方面,2组比较差异均有统计学意义（P〈0.05）,奥司他韦暴露组胎儿畸形及小样儿发生率更低。结论：奥司他韦不增加妊娠流感患者早产、先兆子痫、产时发热、死胎或新生儿死亡等不良结局,并可减少胎膜早破、胎儿畸形和小样儿的发生风险。

英文摘要：

OBJECTIVE To assess safety of oseltamivir against influenza virus infection during pregnancy.METHODS Literatures searched from PubMed,The Cochrane Library,EMbase,CNKI,WanFang,VIP,CBM database,to evaluate quality of studies according to Newcastle-Ottawa Quality Scale（NOS scale）.Meta analysis was performed for results of homogeneous studies by using The Cochrane Collaboration＇s software RevMan5.3.RESULTS Six cohort studies were analyzed in our study,including 1865 pregnant patients who exposed to oseltamivir and 138414 unexposed patients.Compared with the unexposed group,the exposed group had lower risks of premature rupture of membranes（P〈0.05）.No difference was observed in risks for preterm delivery,preeclampsia,occurrence of fever in labor between two groups（P〉0.05）.There was no statistical difference in risks of stillborn,neonatal death or low Apgar score（P〉0.05）.Exposed group had lower risks of fetal malformation and small gestational age（P〈0.05）.CONCLUSION Oseltamivir will not increase adverse fetal outcomes,including preterm delivery,preeclampsia,occurrence of fever in labor,stillborn or neonatal death,and can reduce risks of premature rupture of membranes,fetal malformation and being small for gestational age.